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Preoperative radiochemotherapy and total mesorectal excision surgery is a recommended
standard therapy for patients with locally advanced rectal cancer. However, some subgroups
of  patients beneﬁt more than others from this approach. In order to avoid long-term com-
plications of radiation and chemotherapy, efforts are being made to subdivide T3N0 stage
using advanced imaging techniques, and to analyze prognostic factors that help to deﬁne
subgroup risk patients. Long-course radiochemotherapy has the potential of downsizing
the  tumor before surgery and may increase the chance of sphincter preservation in some
patients. Short-course radiotherapy (SCRT), on the other hand, is a practical schedule that
better suits patients with intermediated risk tumors, located far from the anal margin. SCRT
is  also increasingly being used among patients with disseminated disease, before resectionof  the rectal tumor. Improvements in radiation technique, such as keeping the irradiation
target below S2/S3 junction, and the use of IMRT, can reduce the toxicity associated with
radiation, specially long-term small bowel toxicity.
© 2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
beneﬁt for patients whose tumors are conﬁned to the bowel.  Background
ven though surgery has always been the historical backbone
f rectal cancer treatment, since the ﬁrst Northern Amer-
can experiences of postoperative radiochemotherpy (RCT)1nd Northern European experiences of preoperative exclu-
ive radiotherapy,2 it became evident that adjuvant treatment
ould be an effective way to obtain an outcome improvement.
∗ Corresponding author. Tel.: +34 915202315; fax: +34 915202315.
E-mail address: lcerezo@salud.madrid.org (L. Cerezo).
507-1367/$ – see front matter © 2013 Greater Poland Cancer Centre. Publish
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Preoperative RCT and total mesorectal excision (TME)
surgical procedure is a recommended standard therapy for
patients with locally advanced rectal cancer (LARC), that is
≥T3 and/or ≥N1 disease. However, subgroup analyses in stud-
ies of preoperative treatment have not demonstrated a clinicalwall and who have negative lymph nodes. In the absence of
signiﬁcant survival advantages, it seems appropriate to focus
our attention on deﬁning beneﬁts precisely and on selecting
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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treatment options according to risk. Compelling reasons not to
treat all patients with radiation, either preoperatively or post-
operatively, include the risks of substantial toxic effects and
long-term complications, specially the detrimental effects on
bowel function.
The selection of a treatment modality depends on
factors such as tumor histology, size, location, mobility,
anatomic constraints, patient age, intercurrent medical dis-
ease and the technical expertise of the surgeon and radiation
oncologist.
On the other hand, support is growing for the appealing
concept of “wait and see” or even better “watch and wait”
rather than proceed to radical surgery when a complete clini-
cal response is observed. Hence, the management of patients
who  achieve a complete clinical response is becoming increas-
ingly controversial.3
2.  General  principles  of  radiation  therapy
for rectal  cancer
Radiotherapy is given to bulky primary tumor, positive nodes,
and subclinical pelvic deposits. In resectable tumors, the
main goal is to sterilize the surgical margins and the tissues
at risk for subclinical disease outside them, or to increase
sphincter saving rates by tumor downsizing in low laying
tumors.
A dose between 45 Gy and 50 Gy at 2 Gy is considered ade-
quate to control subclinical disease, thus, this is the dose
needed to sterilize the surgical margins in patients with
resectable tumors. In patients with unresectable tumors, the
dose to control bulky tumors and to promote RO resectability
must be higher, but this is strongly affected by the tolerance
of pelvic organs.
It is known that biologically effective dose is related to the
overall treatment duration and the fraction size. Short-course
large daily fractionations (5 Gy/day, 5 days) should not be
affected by repopulation. Biological effects of such a fraction-
ation, according to the linear-quadratic model, are equivalent
to 37.5 Gy in 2 Gy fractions.4
A prolonged interval before surgery, using preoperative
long-course approach, could raise some concerns regarding
the probability that metastases may develop in the meantime.
Irradiation quickly reduces the number of viable tumor clono-
gens available for metastasis, thus, it seems reasonable to
assume that preoperative RT eliminates the production of new
micrometastases during treatment or in the interval between
irradiation and surgery.
Concomitant chemotherapy can further reduce the occur-
rence of systemic metastases, but the exact contribution
of chemotherapeutic agents to the ﬁnal effect of treatment
remains largely unknown. Better models to determine the
mechanisms of radiosensitization and the therapeutic index
of a treatment are needed.
No trial has ever shown that CRT or RT increase sphincter
5,6saving, with the exception of the randomized Lyon R 96-
2 trial which demonstrated not only sphincter preservation
but organ (rectum) preservation after 10 years follow-
up.7,8iotherapy 1 8 ( 2 0 1 3 ) 353–362
3.  Evidence  of  beneﬁts  in  literature  about
preoperative  radiotherapy:  why  adding  a
neoadjuvant  treatment  to  surgery?
Surgical resection is the cornerstone of curative treatment for
rectal cancer. Tumors in the upper and middle rectum can
usually be managed with low anterior resection or coloanal
anastomosis with preservation of the anal sphincter. For lower
rectal tumors, with a distal edge of up to 6 cm from the
anal verge, abdominoperineal resection (APR) has long been
considered to be the standard operation. For patients with
small rectal cancers that are conﬁned to the rectal wall (T1
or T2), local excision techniques may offer local control rates
that are comparable to APR, while preserving sphincter func-
tion, but this can not be considered a standard treatment
for T2 rectal cancer. For patients with larger or more  inva-
sive tumors, neoadjuvant RCT has been utilized to promote
tumor regression in an attempt to convert a planned APR into
a sphincter-sparing surgical procedure.
The only deﬁnitive indication for neoadjuvant CRT, sup-
ported by results of randomized trials, is the presence of T3
or T4 rectal cancer. In 1997 the Swedish trial showed both a
5 year local control and survival improvement by adding pre-
operative RT (alone, with a short course – SCRT – schedule of
fractionation), even if the group of patients underwent non
standardized surgery.9
TME was developed after the recognition that discontinu-
ous tumor deposits are often present in the lymphovascular
tissue that surrounds the rectum (the mesorectum); left in
place, such residual deposits are most likely the origin of local
treatment failure. With the introduction of the TME, the local
recurrence rates have dropped from 40 to 10 percent, approx-
imately. Some physicians claim that adjuvant radiotherapy is
not necessary if patients undergo resection with TME; how-
ever, it must be emphasized that TME series include patients
with T1-2 N0 disease and allow identiﬁcation and exclusion of
patients with more  advanced disease, compared with patients
treated in the adjuvant trials in which more  conventional
surgery is performed. In the TME era, the Dutch trial obtained,
for a population of T1–3 patients, a signiﬁcant beneﬁt for the
arm adding short course radiation therapy (SCRT) to certiﬁed
TME surgery (25 Gy in 5 fractions); this beneﬁt remains at 6
year of median follow-up.10
Data from randomized trials suggest that the preoperative
approach is associated with a more  favorable long-term tox-
icity proﬁle and fewer local recurrences than postoperative
therapy The German study CAO/ARO/AIO-94 compared preop-
erative versus postoperative approach, delivering 45–50.4 Gy in
25–28 fractions with concomitant chemotherapy (CT).The two
arms were similar apart from the administration of a boost
of 5.4 Gy in the postoperative arm. Preoperative approach
signiﬁcantly decreased toxicity, and local recurrence, more-
over, it increased sphincter preservation. The main outcomes
remained at 11 years follow up.11
In the NSABP trial R-03, preoperative RCT was directly com-
12pared to postoperative RCT. Preoperative RCT consisted of
one cycle of bolus weekly 5-FU and leucovorin for six weeks,
two courses of 5-FU and leucovorin (daily for ﬁve days during
the ﬁrst and ﬁfth course of RT) concomitant with 50.4 Gy pelvic
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rradiation, surgery, then four cycles of postoperative weekly
olus 5-FU and leucovorin. Postoperative therapy consisted of
urgery, one cycle of weekly bolus 5-FU plus leucovorin, two
ycles of 5-FU and leucovorin concomitant with pelvic RT as
escribed above, then four cycles of weekly bolus 5-FU and leu-
ovorin. Accrual did not reach planned levels, and the protocol
as  closed early. In the ﬁnal analysis of 267 enrolled patients,
he clinical pathologic complete response rate after preopera-
ive RCT was 15%. While preoperative therapy was associated
ith a signiﬁcantly higher rate of 5-year disease-free survival
DFS, 65 versus 53 percent), there was only a trend toward bet-
er overall survival (OS, 75 versus 66 percent, p = 0.065), and
o difference in locoregional control (5-year cumulative inci-
ence of locoregional recurrence was 11 percent in both arms)
r sphincter preservation.
In contrast, Park et al.13 did not ﬁnd differences in acute or
ate toxicity between preoperative and postoperative CRT in
40 locally advanced rectal cancer patients. In this random-
zed trial, the patients with low-lying tumors, the preoperative
RT arm had a higher rate of sphincter preservation (68% vs.
2%, p = .008).
.  International  guidelines
ecommendations:  what  is  worldwide
uggested?
wo of the most representative international guidelines, the
ational Comprehensive Cancer Network (NCCN)14 and the
ational Cancer Institute (NCI)15 suggest preoperative LCRCT
s preferable: that seems in line with the traditional clinical
pproach in North America. The European scenario is quite
ore  various, since the UK and Northern regions seem to pre-
er more  often SCRT schedules while the other countries tend
o prefer LCRCT (of course with case variations). Table 1 reports
ecommendations from the most commonly used national
nd international guidelines. The International Conference
n ‘Multidisciplinary Rectal Cancer Treatment: Looking for an
uropean Consensus’ (EURECA-CC2) was organized in Italy,
ith the aim to focus on the main agreement and controver-
ies about the rectal cancer management.16 For the treatment
f intermediate stages there was a moderate consensus that
CRT reduces local relapses, LCRCT was also considered a pri-
ary option; for more  advanced unresectable lesions, LCRCT
as the preferred schedule. A key role of MRI  based staging
s being introduced now to tailor the preoperative modalities
SCRT/LCRCT) choice, giving more  option to LCRCT when the
esorectal fascia is threatened.
The optimal management of clinical T3N0 rectal cancer
s unclear. Some of these patients have a sufﬁciently favor-
ble prognosis, therefore questions have been raised as to the
ecessity of postoperative adjuvant therapy after upfront TME.
thers have questioned the utility of upfront CRT, particularly
or those involving the upper rectum, given the favorable low
ates of local recurrence after TME  alone in the Dutch TME
rial and retrospective analyses. On the other hand, as many
s one-ﬁfth of these patients may be understaged by preopera-
ive imaging. In a review of 188 patients with TRUS/MRI staged
3N0 rectal cancer patients who  received preoperative RCT, 41
22%) were found to have pathologically positive mesorectaltherapy 1 8 ( 2 0 1 3 ) 353–362 355
lymph nodes at the time of surgery.17 Given the downstaging
effect of RCT, it is likely that an even larger number of these
patients would have been found to have node-positive disease
(and recommended for postoperative adjuvant therapy) had
surgery been undertaken initially. Thus, given the limitations
of current imaging, all patients with cT3N0 rectal cancer by
TRUS or MRI should be considered candidates for preoperative
CRT.
Another issue emerged from different studies, both includ-
ing LCRCT and SCRT, is the negative impact on outcome
deriving from positive or involved circumferential resection
margins (CRM+/close ≤ 1 mm).  CRM is deﬁned as the margin
created around the mesorectum, which is at risk both from
direct involvement by the tumor and from the lymph nodes
that lie just under the mesorectal fascia, if not completely
removed. There are higher rates of metastatization and even
lower survival if CRM is directly involved or if it is inferior to
1 mm.18 LCRCT has the potential to decrease the CRM posi-
tivity rates.5
High quality evidence to support a clear beneﬁt from preop-
erative RCT as compared to initial surgery for other subgroups
of patients with rectal cancer is lacking. For instance, preoper-
ative RCT can be an appropriate option for patients with T1/2
tumors and clinically positive nodes. Also, for patients who
have distal mobile rectal cancers, not amenable to local exci-
sion, preoperative RCT might allow sphincter-preserving LAR
rather than an APR in some cases.19 The German trial of preop-
erative versus postoperative CRT demonstrated that patients
undergoing preoperative CRT were twice as likely to undergo
a sphincter-sparing operation (39 versus 19 percent).20 How-
ever, the absolute rates of APR in the two  cohorts were not
signiﬁcantly different. In all these settings, patients must
understand that there is a possibility that postoperative CRT
might not be needed, based upon the ﬁnal pathologic stage
if surgery is performed initially. However, due to the down-
staging effect, pathologic nodal staging is unreliable after CRT.
Thus, if this approach is followed, a six-month course of post-
operative chemotherapy (CT) is recommended.
5.  Long-course  versus  short-course
radiochemotherapy
Rectal cancer is considered to have a very long growing time,
but retrospective analyses of rectal cancer trials show that the
growth rate for subclinical tumor deposits has an average dou-
bling time for microscopic foci not longer than 14 days and
could be as short as 4 days, and also that the tumor control
probability curves for local control were shifted to higher doses
as the overall duration of the preoperative radiation therapy
was increased.
Main potential advantages from the use of LCRCT over
SCRT are: the safe association with concomitant chemother-
apy, the downstaging before surgery, the induction of
resectability for originally unresectable lesions, the efﬁcacy in
management of mesorectal fascia involvement presentations,
and potential increase of sphincter saving rates.
One of the main advantages of LCRCT is the potential
downstaging obtainable before surgery. It is quite well known
that downstaging is signiﬁcantly correlated with better
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Table 1 – National and International Guidelines for locally advanced rectal cancer.
World
Congress on GI
Cancer, 2007
French
Guidelines,
2007
Norwegian
Guidelines,
2008
EURECA
Consensus,
2008
Dutch
Guidelines,
2008
Danish
Guidelines,
2009
ESMO,
2010
Expert
Opinion in
Spain, 2011
NCCN,
2012
PDQ,
2012
T3,N0 or anyT N+ LCRTCT (SCRT
as an
alternative for
earlier stages)
(RTCT can also
be considered
for T2N0
disease)
SCRT or
LCRTCT (no
tx of T3N0
disease with
CRM >1 mm)
SCRT (or
LCRTCT if
CRM ≤3 mm)
If  resectable:
SCRT or
LCRTCT
SCRT
(LCRTCT only
for positive
CRM or ≥4
LNs involved)
(include also
T2 disease)
LCRTCT for
midrectal T3
disease with
CRM <5 mm;
and for all
low-rectal T3
disease
If CRM negative
at MRI: RT alone
or LCRTCT (as
alternative)
(Also include T4
disease with
vaginal or
peritoneal
involvement
only)
LCRTCT [SCRT as
alternative for
non-ﬁtting pts or
in case of
suboptimal
LCRTCT)
(Include pts with
CRM <1 mm)
LCRTCT LCRTCT
T4,anyN LCRTCT (SCRT
as alternative
for earlier
stages)
SCRT or
LCRTCT
LCRTCT If not
resectable:
LCRTCT
SCRT
(LCRTCT only
for positive
CRM or ≥ 4
LNs involved)
LCRTCT for
mid- and
low-rectal T4
disease
If not resectable:
LCRTCT
(Also include cT3
disease with
CRM positive on
MRI)
LCRTCT LCRTCT
(including
unresectable
lesions)
LCRTCT
Modiﬁed by Cellini, F. and V. Valentini (2012). Oncology (Williston Park) 26(8): 730–735, 741 24.
CRM = circumferential resection margin; ESMO = European Society of Medical Oncology; EURECA = European Rectal Cancer; LN = lymph node; MRI = magnetic resonance imaging; NCCN = National
Comprehensive Cancer Network; PDQ = Physician Data Query; pt = patient; SCRT = short course radiotherapy; LCRTCT = long course radiochemotherapy; tx = treatment.
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utcomes, in particular with highly favorable locoregional
ontrol (LRC) rates for pathological complete response.21,22
ecently, a pooled analysis of randomized trials using pre-
perative RCT identiﬁed a subgroup of patients with better
ndicators for pathological complete response (pCR), in terms
f local control, distant metastases and overall survival.23
Another potential effect of downstaging and downsiz-
ng is the conversion into resectable an unresectable tumor;
his is evident and widely accepted among the international
uidelines.14,16 Some clinical experiences are now trying to
valuate if SCRT with a longer interval before surgery can
ncrease the pCR rates.
The downstaging obtainable with a LCRCT approach has
lso the potential to increase the sphincter preservation rates,
lthough this is still a debated issue.24
.1.  Concomitant  chemotherapy
n optimized choice of concomitant chemosensitization
ould enhance LCRCT treatment’s efﬁcacy. Several random-
zed trials and a meta-analysis have directly addressed the
uestion of whether the concurrent administration of CT
ith conventional fractionation RT is critical to the success
f this approach. EORTC 22921 examined both the beneﬁt of
oncurrent RCT (using a ﬁve-day bolus 5-FU and leucovorin
egimen during weeks 1 and 5 of RT) versus preoperative RT
lone (45 Gy over ﬁve weeks) and the contribution of adjuvant
T (four cycles of bolus 5-FU and leucovorin), using a 2 × 2
actorial design. Compared to RT alone, patients undergoing
reoperative RCT had a signiﬁcantly higher rate of pathologic
omplete responses (pCR, 14 versus 5 percent), signiﬁcantly
ess advanced pT and pN stage, and fewer cases with venous,
erineural, or lymphatic invasion.25 Local failure rates were
igniﬁcantly lower in all three groups receiving CT, regardless
f whether it was given prior to or following surgery. Neverthe-
ess, OS was comparable in all four groups, as well as PFS in
atients receiving preoperative CRT versus RT alone (56 versus
4 percent) or adjuvant CT versus no adjuvant chemotherapy
58 versus 52 percent, p = 0.13).
In the randomized trial conducted by Braendengen el al.,26
hich included 207 patients with T4, non resectable tumors
reated between 1996 and 2003 with either RT alone (50 Gy)
r CRT (ﬂuorouracil/leucovorin), more  pathologic complete
esponses were found in the CRT arm (16% vs. 7%). CRT also
mproved local control at 5 years (82% vs. 67; p = 0.03), time
o treatment failure (63% vs. 44%; p = .003) and cancer-speciﬁc
urvival (72% vs. 55%; p = .02), compared with RT alone.
The standard association for LCRCT is with 5-FU in contin-
ous infusion,14 but some evidence reported the equivalence
f oral capecitabine.27,28 The efﬁcacy of the integration of
xaliplatin into the concurrent schedules is still controver-
ial; some evidence suggests no beneﬁt from such association
ue to increased toxicity without a signiﬁcant improvement
f pCR rates. That was basically reported by the STAR-
129 and the ACCORD 1230 trials, whereas the German trial
CAO/ARO/AIO-04)31 reported on signiﬁcant improvement for
he oxaliplatin-based arm. A clearer picture will be available
hen all these studies provide long term results. In the mean
ime, the vast majority of experts agree that oxaliplatin musttherapy 1 8 ( 2 0 1 3 ) 353–362 357
not be given concurrently with 5FU or capecitabine and radio-
therapy.
Associated with a high potential as it is, the use of molecu-
lar targeted therapies, like cetuximab and bevacizumab in the
neoadjuvant setting, is still under evaluation due to some con-
cerns in terms of efﬁcacy and toxicity and associated risk of
postoperative complications. Patient selection, based on gene
expression proﬁles, seems to be a potential key to deﬁne the
most suitable patients to receive these complex treatments.
5.2.  Direct  comparison  of  LCRTCT  vs.  SCRT:
randomized  trials
Two randomized trials directly compared LCRCT against SCRT:
the so-called “Polish trial” evaluated 316 cT3 pts with lesion
lying above the anorectal ring; TME was not performed for
all patients. As expectable, the LCRCT provided higher rates
of pCR (16%-LCRCT; 1%-SCRT), lower rates of positive CRM
(4%-LCRCT; 13%-SCRT), and higher rates of acute toxicity
(16%-LCRCT; 1%-SCRT) without any signiﬁcant difference in
locoregional control and survival.5
Another experience from Australia and New Zealand also
randomized patients into two arms: SCRT immediately fol-
lowed by surgery plus 6 cycles of adjuvant CT, or 50.4 Gy with
continuous infusion of 5-FU, 225 mg/m2, followed by surgery
after 4–6 weeks; 326 T3 any N pts were enrolled. Authors found
no statistically signiﬁcant difference for survival (74 vs. 70%
at 5 years) or locoregional recurrence (8 vs. 4% at 3 years)32
(Table 2).
Some studies with the same purpose are also ongo-
ing: the Stockolm III randomizes to LCRT (no concomitant
chemotherapy) or SCRT (with immediate surgery) or SCRT
(with delayed surgery). Interestingly, an interim report found
higher postoperative complication rates correlated to SCRT
with immediate surgery (associated to impaired postoperative
leukocyte counts).33,34
A German trial is comparing now LCRCT vs. SCRT (early
surgery). This trial is supposed to accrue over 700 pts.
5.3.  Short  course  radiotherapy  and  delayed  surgery
The interest in this scheme has increased in the last few years,
as delayed surgery can be performed 6–8 weeks after treat-
ment. In the study by Radu35 46 patients with non-resectable
rectal cancer were treated between 2002 and 2005. The ﬁrst
group (A) had no metastases (T4NXM0), whereas the other
two groups (B + C) had metastases (T4NXM1). In group (B),
patients had predominantly loco-regional disease and were
not candidates for CRT due to advanced age or comorbidi-
ties. In group (C), CRT was given with the intention to perform
surgery of both the primary and the secondary tumor if suf-
ﬁcient regression was seen. SCRT was well tolerated by most
patients. Only 3 patients suffered diarrhea grade 4. One patient
in group (C) died due to sepsis with fever and neutropenia. All
patients underwent delayed surgery. R0 or R1 was obtained
in 22 patients of group (A) (92%), 4 in group (B) (44%), and 6
in group (C) (46%). Pathologic complete response was seen in
4 patients, 2 in group (A) and 2 in group (C). There were no
postoperative deaths.
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Table 2 – Randomized studies comparing short-course RT vs. long-course RT.
BJS 2006 Polish study JCO 2012 RTOG 01.04
5 × 5 + TME 50.4/5FU
bolus + TME
5 × 5 + TME 6
adjuvant CT
50.4/5-FU ci + TME
4 adjuvant CT
N 155 157 163 163
Follow-up 4 years 5.9 years
Local failure 9% 14.2% 7.5% 4.4%
DFS 58% 55% 73% 70%
OS 67% 62% 74% 70%
G3-G4 GI 3.2% 5.1%
al; OSG3-G4 Global 10.1% 7.1% 
Ci, continuous infusion; DFS, disease-free survival; GI, gastrointestin
Other group36 used MRI  for the evaluation of the resection
margin in patients with contraindication for CT due to age,
performance status, or comorbidities. Patients were treated
with SCRT and delayed surgery. Forty-three patients, with a
mean age of 82 years, were selected. Of the 42 patients who
received RT, 26 (61%) could undergo surgery. R0 was obtained
in 22 patients, and R1 or R2 in 2 patients each. The treatment
was well tolerated. Two patients required hospitalization due
to diarrhea. One patient presented with delayed toxicity of the
small intestine, which was attributable to RT. After a mean
follow-up of 18 months, no local relapse was reported in the
R0 and R1 groups. Mean survival for the whole population was
23 months, but increased to 44 months in the group of patients
who  underwent surgery.
The improved survival due to the progress in CT and bio-
logic agents over the last years, has caused surgical procedures
to become more  frequent among patients with disseminated
disease. This has favored the alternate use of SCRT and FOL-
FOX CT. CT would be administered in weeks 1 and 3, and RT
in week 5, followed by two more  cycles of FOLFOX in weeks 7
and 9, and surgery in week 11.
6.  Watch  and  wait  approach
A proportion of patients who receive preoperative RCT for
locally advanced (T3/T4, NX) rectal cancer achieve a complete
clinical response and a pathologic complete response in the
region of 15–30 percent. The “wait and see” approach is con-
trary to traditional surgical tenets, although radical external
beam RT is considered an acceptable therapeutic option for
patients with rectal cancer who are unﬁt for or refuse surgery.
For tumors in the low rectum, surgeons and oncologists have
collaborated over many  years in the search for less mutilating
approaches. Thus, strategies such as preoperative RCT fol-
lowed by sphincter sparing surgery or local excision, or local
excision followed by pelvic RCT have been explored.
Some radiation oncologists have reported that locally
applied endocavitary radiotherapy is an accepted method of
radical treatment for clinically staged T1 and T2 tumors in
the mid  and distal rectum. Advocates of this procedure treat
until response and accept that lack of response is an indi-
cation for surgical excision. This technique requires rigorous
patient selection, experience, and operator skill in the deliv-
ery of superﬁcial radiation directly to the tumor on repeated
occasions. The results of the Lyon experience for 101 T15.8% 8.2%
, overall survival. p ≤ 0.05.
tumors demonstrate a local control of 90 percent. However,
the outcome for T2 tumors is less favorable with reported local
recurrence rates of up to 22% of cases.37 In a larger series of 44
patients combining external RT and 50 KV contact X-ray ther-
apy, the rate of local failure for T2 tumors was <20%, and no
nodal failure was reported.38
The evidence from an initial observational study in Brazil39
has been enthusiastically received in the oncological forum,
and support is growing for the concept of “wait and see” when
a clinical complete response is observed after neoadjuvant
RCT for locally advanced rectal cancer. This concept would
be better deﬁned as “watch and wait”, meaning that the ﬁrst
step after CRT would be to watch with rectoscopy to even-
tually ﬁnd a clinical complete response and follow closely. In
their last update, a total of 306 clinically staged T2–T4 patients
were treated with RCT, of whom 99 achieved a cCR and only
six were described as experiencing a local recurrence.40 These
unique data are very close to the data reported by Papillon
in 199041 and more  recently by Maas.42This approach may be
particularly relevant to European countries where screening
programs for rectal cancer are implemented, which should
deﬁne a much greater proportion of early T1/T2 tumors,
and the fact that we  have an increasingly aging popula-
tion, although the response after neoadjuvant RCT is not
easy to assess, being diffusion MRI  and/or PET-CT under
investigation.43 These conservative approaches would only be
acceptable if close observation and frequent rectoscopy are
performed.
The available evidence remains insufﬁcient to support
this policy and is not robust enough to risk the well-being
of a young, ﬁt patient, although it could be justiﬁed in
elderly patients with early-stage tumors and considerable
comorbidity. Furthermore, CRT followed by endocavitary irra-
diation would be a good option for selected patients, with
the aim of organ (rectum) preservation, and not only sphinc-
ter preservation as has been demonstrated in the Lyon R96-2
trial.7,8 Prospective, randomized studies in this ﬁeld are clearly
required to duplicate the Lyon R96-2 trial, and change the clin-
ical practice..
7.  Technical  aspects  of  the  treatmentGastrointestinal toxicity is the main acute toxicity observed in
the preoperative setting. Acute grade 3 or greater diarrhea is
observed in 12–25% of patients.44,20 Moreover, several studies
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nd the 45 Gy isodose surface (green) encompasses de PTV.
ave demonstrated a statistically signiﬁcant association
etween the development of G3 or greater acute small bowel
SB) toxicity and the volume of SB irradiated.45–48 V15 have
een postulated as a reliable dose-volume parameter to be
ssessed during dose plan evaluation; patients in whom more
han 150 cc of small bowel receive ≥15 Gy appeared to have
he greatest risk of grade 3 small-bowel toxicity.
It is now agreed that the target must be kept below the S2/S3
unction in most cases.49 In the ACCORD 12 trial, 3D conformal
T was used to irradiate small posterior volume to 50 Gy. At 3
ears, grade 3 toxicity was less than 5% and the rate of local
ecurrence was <3% in the Capox arm6
In this scenario, intensity-modulated radiation therapy
IMRT) has been proposed as a technique to reduce the tox-
city associated with CRT. IMRT  could potentially reduce the
ose to the small bowel, thereby reducing the gastrointestinal
ide effects caused by radiation, even when combined with
ore effective radiation sensitizers. Appropriate delineation
f target volumes and organs at risk is critical due to the high
egree of conformity achieved with IMRT.50 Dosimetric stud-
es have shown that IMRT  has better normal tissue sparing
bility than other radiation techniques51–54 (Fig. 1). However,
nly a limited number of clinical studies have been reported
o date.55–57 These prospective trials have demonstrated the
easibility of treating with IMRT  and concomitant chemother-
py, but more  data regarding acute and long-term toxicity are
ecessary.
Preliminary results of the RTOG 0822 phase II study of pre-
perative IMRT  with Capecitabine and Oxaliplatin in LARC
atients58 suggest a reduction in ≥ Grade 2 toxicity, butThe 47.5 Gy isodose surface (red) encompasses the CTV,
toxicity data analysis is currently being performed toward
identifying optimal IMRT planning criteria for future studies.
Simultaneously, the University of Navarra Hospital has car-
ried out a prospective study of preoperative chemo-IMRT in
rectal cancer.51,55,56,59 The treatment protocol included simul-
taneous combination of capecitabine and oxaliplatin (CAPOX)
with 47.5 Gy hypofractionated IMRT  (2375 Gy/fx). A total of 140
patients with LARC were analyzed. No grade 4 toxicity was
reported. Grade 1–2 rectitis was the most frequently observed
toxicity (74% of patients), and this could be attributed to oxali-
platine. Grade 3 diarrhea was reported in 13 patients (9%),
and grade 3 rectitis in 14 patients (10%). After surgery, 50% of
patients achieved a major pathologic response. With a median
follow-up of 5.2 years, only three patients presented locore-
gional failure (2.1%). The 8-year OS and DFS rates were 89%
(95% CI: 96.3–105.2) and 78% (95% CI: 88–99.5), respectively,
and the distal failure rate was 16%. This treatment proto-
col is feasible and safe, small bowel toxicity rate is low, and
produces major pathological responses in about 50% of the
patients. Although no ﬁrm conclusions can be drawn from
this phase II trial, these results indicate that hypofractionated
Capecitabine – IMRT achieve a good clinical outcome in LARC
patients.
8.  ConclusionsEven if the need for neoadjuvant treatment for locally
advanced rectal cancer is clear enough, the optimal strategy
has yet to be deﬁned. New clinical evidence is needed to
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deﬁnitely deﬁne which treatment schedule is superior, but
also longer follow-up evaluation could be determinant, since
for rectal cancer patients (as opposed to pure colon cancer)
the trend of local control and survival continues to decrease
after 5 years. At present, LCRCT seems to have greater clinical
versatility and can allow high personalization of treatment.
On the other hand, SCRT can be used in patients with inter-
mediated risk rectal tumors, located more  than 5 cm away
from the anal margin, with a non-threatened circumferential
resection margin and with a low risk of lymph node involve-
ment. The use of a large shared database could favor the
individualization of surrogative end-points to address the
future research. The Watch and Wait policy after preoperative
RCT can be an attractive subject of future research for small
tumors, but can not be considered standard treatment at
the present time. In order to reduce the intestinal toxicity,
keeping the target volume below S2/S3 junction is generally
recommended. The use of IMRT  in the preoperative setting of
LARC patients is based on a strong rationale and dosimetric
evidence of small intestine irradiated volume.
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